---
title: "002349.SZ (002349.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002349.SZ/news.md"
symbol: "002349.SZ"
name: "002349.SZ"
parent: "https://longbridge.com/en/quote/002349.SZ.md"
datetime: "2026-03-10T03:12:39.899Z"
locales:
  - [en](https://longbridge.com/en/quote/002349.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002349.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002349.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/002349.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002349.SZ/news.md)


# 002349.SZ (002349.SZ) — Related News

### ["Performance" Novartis' net profit fell 15% last quarter, expects core operating profit to decline for the first time in six years this year](https://longbridge.com/en/news/274773576.md)
*2026-02-04T07:29:52.000Z*
> One of Switzerland's two major pharmaceutical giants, NOVARTIS AG, stated that its best-selling heart disease drug Entre

### [JINGHUA PHARM: Subsidiary's environmental pollution lawsuit ruling, fines and penalties offset, no further payment required](https://longbridge.com/en/news/270788915.md)
*2025-12-25T11:31:01.000Z*
> JINGHUA PHARM announced that its subsidiary Ningxia Senxuan was sued for environmental pollution, and on December 23, 20

### [](https://longbridge.com/en/news/267470205.md)
*2025-11-26T07:29:40.000Z*
> JINGHUA PHARM stated on the interactive platform that the company is laying out products such as Mabalasavir, and the pr

### [JINGHUA PHARM: The controlled-release capsule of carbidopa and levodopa has obtained the drug registration certificate](https://longbridge.com/en/news/265286662.md)
*2025-11-11T08:08:03.000Z*
> JINGHUA PHARM recently obtained two drug registration certificates for Carbidopa/Levodopa Extended-Release Tablets issue

### [JINGHUA PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 176 million yuan, a year-on-year increase of 7.39%](https://longbridge.com/en/news/263288083.md)
*2025-10-29T12:29:02.000Z*
> According to the Zhitong Finance APP, JINGHUA PHARM released its third-quarter report for 2025. In the first three quart

### [JINGHUA PHARM: The company's medical sodium alginate wound dressing has obtained a medical device registration certificate](https://longbridge.com/en/news/257857999.md)
*2025-09-18T07:54:31.000Z*
> On September 18th, JINGHUA PHARM announced that its medical sodium alginate wound dressing has obtained the "Medical Dev

### [JINGHUA PHARM's subsidiary LuHuaSenXuan leads the formulation of an industry standard approved by the National Standardization Administration](https://longbridge.com/en/news/257501578.md)
*2025-09-16T08:53:02.000Z*
> According to the Zhitong Finance APP, JINGHUA PHARM announced that the industry standard for "1,3-Dioxolane" led by its 

### [JINGHUA PHARM: Net profit of 131 million yuan in the first half of 2025, a year-on-year decrease of 3.54%](https://longbridge.com/en/news/255220483.md)
*2025-08-29T13:18:10.000Z*
> JINGHUA PHARM announced that in the first half of 2025, operating revenue was 731 million yuan, a year-on-year increase